Abdom Radiol (NY)
- LIANG JP, Yin L, Gao LK, Yin L, et al
Contrast-enhanced CT in the differential diagnosis of bladder cancer and
paraganglioma.
Abdom Radiol (NY). 2024 Mar 19. doi: 10.1007/s00261-024-04217.
- CHAI JL, Roller LA, Liu X, Lan Z, et al
Performance of VI-RADS in predicting muscle-invasive bladder cancer after
transurethral resection: a single center retrospective analysis.
Abdom Radiol (NY). 2024 Mar 19. doi: 10.1007/s00261-024-04245.
Ann Med
- SUN X, Liu C, Zhang C, Zhang Z, et al
Nomogram for predicting postoperative ileus after radical cystectomy and urinary
diversion: a retrospective single-center study.
Ann Med. 2024;56:2329125.
Arch Ital Urol Androl
- LEONARDI R, Ambrosini F, Cafarelli A, Calarco A, et al
Office-based management of non-muscle invasive bladder cancer (NMIBC): a position
paper on current state of the art and future perspectives.
Arch Ital Urol Androl. 2024 Mar 19:12404. doi: 10.4081/aiua.2024.12404.
- MOUSSA M, Abou Chakra M, Shore ND, Papatsoris A, et al
Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder
cancer (NMIBC) patients among Arab urologists.
Arch Ital Urol Androl. 2024 Mar 19:12244. doi: 10.4081/aiua.2024.12244.
BJU Int
- DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
Trimodal therapy effect on survival in urothelial vs non-urothelial bladder
cancer.
BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
- LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
Gynaecological organ involvement in females undergoing radical cystectomy: a
multicentre study.
BJU Int. 2024;133:474-479.
BMC Immunol
- MOADAB A, Valizadeh MR, Nazari A, Khorramdelazad H, et al
Association of interleukin-17A and chemokine/vascular endothelial growth
factor-induced angiogenesis in newly diagnosed patients with bladder cancer.
BMC Immunol. 2024;25:20.
BMC Urol
- YE J, Zheng L, Chen Z, Wang Q, et al
Serum alpha-hydroxybutyrate dehydrogenase as a biomarker for predicting survival
outcomes in patients with UTUC after radical nephroureterectomy.
BMC Urol. 2024;24:62.
- IKUMA S, Akatsuka J, Takeda H, Endo Y, et al
Determining the clinicopathological significance of the VI-RADS >==4 group: a
retrospective study.
BMC Urol. 2024;24:63.
Br J Cancer
- JONES RJ, Crabb SJ, Linch M, Birtle AJ, et al
Systemic anticancer therapy for urothelial carcinoma: UK oncologists'
perspective.
Br J Cancer. 2024;130:897-907.
Cancer Epidemiol
- WU KY, Cheong IS, Lai JN, Hu CY, et al
Risk of secondary primary malignancies in survivors of upper tract urothelial
carcinoma: A nationwide population-based analysis.
Cancer Epidemiol. 2024;89:102536.
Cell Mol Biol Lett
- LV L, Wei Q, Zhang J, Dong Y, et al
IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.
Cell Mol Biol Lett. 2024;29:39.
Clin Pharmacol Ther
- DE CARLO A, Tosca EM, Fantozzi M, Magni P, et al
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive
Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma.
Clin Pharmacol Ther. 2024;115:825-838.
Comb Chem High Throughput Screen
- LIU F, Li J, Zhou B, Shen Y, et al
The Role of Emodin in the Treatment of Bladder Cancer based on Network
Pharmacology and Experimental Verification.
Comb Chem High Throughput Screen. 2024.
Eur J Epidemiol
- VAN DEN BRANDT PA
Diabetes and the risk of bladder cancer subtypes in men and women: results from
the Netherlands Cohort Study.
Eur J Epidemiol. 2024 Mar 16. doi: 10.1007/s10654-024-01100.
Eur Rev Med Pharmacol Sci
- WANG JF, Gong YQ, He YH, Ying WW, et al
Author Correction: High expression of MMP14 is associated with progression and
poor short-term prognosis in muscle-invasive bladder cancer.
Eur Rev Med Pharmacol Sci. 2024;28:1640.
Eur Urol
- COX A, Klumper N, Stein J, Sikic D, et al
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic
Evolution.
Eur Urol. 2024;85:328-332.
- LIEDBERG F, Bobjer J
Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma
After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data.
Eur Urol. 2024;85:392.
- PIRAMIDE F, Turri F, Amparore D, Fallara G, et al
Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted
Radical Cystectomy and Systematic Review of Clinical Outcomes.
Eur Urol. 2024;85:348-360.
- DAHM P, Ergun O, Sathianathen N
Re: Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, et al. Robot-assisted
Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and
Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using
Randomized Contr
Eur Urol. 2024;85:e116.
- LINSCOTT JA, Meeks JJ, Dyrskjot L, Li R, et al
The Elusive Horizon: Biomarkers in Urothelial Carcinoma.
Eur Urol. 2024;85:317-319.
- ALFRED WITJES J, Bruins HM, Carrion A, Cathomas R, et al
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and
Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024)
17-31].
Eur Urol. 2024 Mar 15:S0302-2838(24)02194-8. doi: 10.1016/j.eururo.2024.
Eur Urol Open Sci
- DE JONG FC, Ifle IG, van der Made AC, Kooper D, et al
A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated
with Radiotherapy.
Eur Urol Open Sci. 2024;62:131-139.
- HAN H, Oh TJ, Heo JE, Lee J, et al
Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for
Monitoring Recurrence of Non-muscle-invasive Bladder Cancer.
Eur Urol Open Sci. 2024;62:99-106.
Front Immunol
- BERGMAN DR, Wang Y, Trujillo E, Fernald AA, et al
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and
presents therapeutic possibilities in an agent-based model.
Front Immunol. 2024;15:1358019.
Front Oncol
- CHEN Y, Shi K, Fu X, Guo H, et al
Diagnostic and prognostic potential of exosome non-coding RNAs in bladder cancer:
a systematic review and meta-analysis.
Front Oncol. 2024;14:1336375.
- PAVAN N, Scaggiante B
Editorial: Liquid biopsy in the detection and prediction of outcomes in bladder
cancer.
Front Oncol. 2024;14:1391466.
- TAO T, Chen Y, Shang Y, He J, et al
SMMF: a self-attention-based multi-parametric MRI feature fusion framework for
the diagnosis of bladder cancer grading.
Front Oncol. 2024;14:1337186.
Future Oncol
- CRITCHLOW S, Bullement A, Crabb S, Jones R, et al
Cost-effectiveness analysis for avelumab first-line maintenance treatment of
advanced urothelial carcinoma in Scotland.
Future Oncol. 2024;20:459-470.
Gan To Kagaku Ryoho
- KOMORI K, Koyama K, Shimizu K, Kanemoto R, et al
[A Case of Colon Metastasis after Surgery for Left Renal Pelvis Cancer].
Gan To Kagaku Ryoho. 2024;51:340-342.
Heliyon
- WANG Y, Wang J, Liu Y, Wang X, et al
Multidimensional pan-cancer analysis of HSPA5 and its validation in the
prognostic value of bladder cancer.
Heliyon. 2024;10:e27184.
- DU G, Jiang Z, Qu W, Zhang J, et al
Downstaging guided neoadjuvant strategy shift and bladder preservation in locally
advanced bladder cancer: A case report.
Heliyon. 2024;10:e27685.
- WANG KY, Wang KJ, Shen LL, Wang XH, et al
The down-regulation of GADD45B leads to a conversion of cellular oxidative
phosphorylation to glycolysis and promotes the progression of bladder cancer.
Heliyon. 2024;10:e27427.
Int Immunopharmacol
- WANG C, Yang X
CircRAPGEF5 sponges miR-582-3p and targets KIF3A to regulate bladder cancer cell
proliferation, migration and invasion.
Int Immunopharmacol. 2024;131:111613.
Int J Oncol
- XU M, Gu M, Zhou J, Da J, et al
[Retracted] Interaction of YAP1 and mTOR promotes bladder cancer progression.
Int J Oncol. 2024;64:50.
J Biomol Struct Dyn
- WU H, Jin H, Cai Y
Unveiling therapeutic prospects: targeting MDM-2 in non-muscle invasive bladder
cancer.
J Biomol Struct Dyn. 2024 Mar 18:1-10. doi: 10.1080/07391102.2024.2329799.
J Cancer
- YAO R, Ai B, Wang Z, Shen B, et al
Uncovering Microbial Composition of the Tissue Microenvironment in Bladder Cancer
using RNA Sequencing Data.
J Cancer. 2024;15:2431-2441.
J Cell Mol Med
- WANG Y, Wang J, Zhang L, He J, et al
Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and
therapeutic target.
J Cell Mol Med. 2024;28:1-20.
- DONG C, Hui P, Wu Z, Li J, et al
CircRNA LOC729852 promotes bladder cancer progression by regulating macrophage
polarization and recruitment via the miR-769-5p/IL-10 axis.
J Cell Mol Med. 2024;28:e18225.
J Egypt Natl Canc Inst
- LIU Y, Zhang K, Yang X
CircMCTP2 enhances the progression of bladder cancer by regulating the
miR-99a-5p/FZD8 axis.
J Egypt Natl Canc Inst. 2024;36:8.
J Investig Med High Impact Case Rep
- ARABYAN G, Hambartzhumian R, Lim A, Quizon M, et al
Unusual Urothelial Tumors and Refractory Uremia Due to Balkan Endemic
Nephropathy: A Case Report.
J Investig Med High Impact Case Rep. 2024;12:23247096241238529.
J Med Chem
- QIN X, Wang H, Xu W, Zheng B, et al
A Selective-Tumor-Penetrating Strategy via Unidirectional Direct Transfer for
Intravesical Therapy of Bladder Cancer.
J Med Chem. 2024 Mar 18. doi: 10.1021/acs.jmedchem.4c00060.
J Pathol Clin Res
- ANGELONI M, van Doeveren T, Lindner S, Volland P, et al
A deep-learning workflow to predict upper tract urothelial carcinoma
protein-based subtypes from H&E slides supporting the prioritization of patients
for molecular testing.
J Pathol Clin Res. 2024;10:e12369.
J Sex Med
- CEASAR RC, Ladi-Seyedian SS, Escobar D, Han J, et al
"I think my vagina is still there?": Women's perspectives on sexual function and
dysfunction following radical cystectomy for bladder cancer, a qualitative study.
J Sex Med. 2024 Mar 15:qdae025. doi: 10.1093.
J Transl Med
- LI L, Jiang P, Hu W, Zou F, et al
AURKB promotes bladder cancer progression by deregulating the p53 DNA damage
response pathway via MAD2L2.
J Transl Med. 2024;22:295.
J Vet Med Sci
- YU TW, Yamamoto H, Morita S, Fukushima R, et al
Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and
cats following single oral administration.
J Vet Med Sci. 2024;86:317-321.
JCO Clin Cancer Inform
- EMINAGA O, Lee TJ, La V, Breil B, et al
Electronic Documentation of Intraoperative Observation of Cystoscopic Procedures
Using the cMDX Information System.
JCO Clin Cancer Inform. 2024;8:e2300114.
JCO Precis Oncol
- KEHL KL, Lavery JA, Brown S, Fuchs H, et al
Biomarker Inference and the Timing of Next-Generation Sequencing in a
Multi-Institutional, Cross-Cancer Clinicogenomic Data Set.
JCO Precis Oncol. 2024;8:e2300489.
Mol Biol Res Commun
- TOUALA-CHAILA Z, Abderrahmane RK, Kerroumi S, Yousfi MJ, et al
Association study of the polymorphisms rs2228611 of the DNMT1 gene and rs1569686
of the DNMT3B gene with bladder cancer development in a sample of the Algerian
population.
Mol Biol Res Commun. 2024;13:65-72.
Mol Cancer
- WU J, Lin Y, Yang K, Liu X, et al
Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma
detection: a double-blinded, multicenter, prospective trial.
Mol Cancer. 2024;23:57.
Mol Carcinog
- WANG B, Fan X, Wang L, Wei X, et al
The RNA-binding protein sorbin and SH3 domain-containing 2 are transcriptionally
regulated by specificity protein 1 and function as tumor suppressors in bladder
cancer by stabilizing tissue factor pathway inhibitor.
Mol Carcinog. 2024 Mar 19. doi: 10.1002/mc.23717.
Nan Fang Yi Ke Da Xue Xue Bao
- CHEN S, Zhang S, Fan W, Sun W, et al
[Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice
bearing ectopic bladder cancer xenograft].
Nan Fang Yi Ke Da Xue Xue Bao. 2024;44:210-216.
Nat Commun
- OHARA K, Rendeiro AF, Bhinder B, Eng KW, et al
The evolution of metastatic upper tract urothelial carcinoma through
genomic-transcriptomic and single-cell protein markers analysis.
Nat Commun. 2024;15:2009.
Neoplasma
- YANG J, Xiang H, Cheng M, Jiang X, et al
microRNA-15a-5p suppresses hypoxia-induced tumor growth and chemoresistance in
bladder cancer by binding to eIF5A2.
Neoplasma. 2024;71:60-69.
Noncoding RNA Res
- HASHEM M, Mohandesi Khosroshahi E, Aliahmady M, Ghanei M, et al
Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance
in bladder cancer through operating a broad spectrum of cellular processes and
signaling mechanism.
Noncoding RNA Res. 2024;9:560-582.
Pathol Int
- KIMURA T, Okita Y, Nagumo Y, Chin JM, et al
Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of
bladder cancer cells through its hem-immunoreceptor tyrosine-based activation
motif.
Pathol Int. 2024 Mar 19. doi: 10.1111/pin.13419.
Pol Arch Intern Med
- SKOWRONSKI M, Halicki P, Halicka A
Disseminated BCGitis after intravesical Bacillus Calmette-Guerin therapy in a
patient with bladder cancer.
Pol Arch Intern Med. 2024 Mar 20:16710. doi: 10.20452/pamw.16710.
Sci Rep
- MURAKAMI T, Minami K, Harabayashi T, Maruyama S, et al
Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA
markers in urothelial bladder cancer patients.
Sci Rep. 2024;14:6801.
Toxicology
- WU J, Gao F, Meng R, Li H, et al
Single-cell and multi-omics analyses highlight cancer-associated
fibroblasts-induced immune evasion and epithelial mesenchymal transition for
smoking bladder cancer.
Toxicology. 2024;504:153782.
Urol Int
- DUAN H, Deng Z, Zou J, Zhang G, et al
The efficacy and safety of Hyperthermia intravesical chemotherapy in the
treatment non-muscle invasive bladder cancer:A meta analysis.
Urol Int. 2024 Mar 20. doi: 10.1159/000538373.
Urol J
- PAZIR Y, Esmeray A, Gelmis M, Caglar U, et al
Performance of the EORTC and CUETO Models to Predict Recurrence and Progression
in High-risk Non-muscle-invasive Bladder Cancer Patients.
Urol J. 2024 Mar 17. doi: 10.22037/uj.v20i.7854.
Urol Oncol
- BENBASSAT J
Estimates of the lead time in screening for bladder cancer.
Urol Oncol. 2024;42:110-114.
- CZECH AK, Gronostaj K, Frydrych J, Polok K, et al
The assessment of bladder cancer resectability with bimanual palpation: A
prospective study in laparoscopy and open cystectomy patients.
Urol Oncol. 2024 Mar 19:S1078-1439(24)00335.
World J Urol
- NISHIMURA N, Miyake M, Iida K, Miyamoto T, et al
Treatment patterns and prognosis in patients with Bacillus
Calmette-Guerin-exposed high-risk non-muscle invasive bladder cancer: a
real-world data analysis.
World J Urol. 2024;42:185.
- BAARD J, Cormio L, Dasgupta R, Maruzzi D, et al
Unveiling the challenges of UTUC biopsies and cytology: insights from a global
real-world practice study.
World J Urol. 2024;42:177.
- KLEIN C, Brunelle S, Illy M, De Luca V, et al
Multiparametric Magnetic Resonance Imaging in the follow-up of
non-muscle-invasive bladder tumors after intravesical instillations: a promising
tool.
World J Urol. 2024;42:178.
- ALHAJAHJEH A, Abdulelah AA, Hmeidan M, Kakish D, et al
Gender inequality in genitourinary malignancies clinical trials leadership.
World J Urol. 2024;42:174.
- ROSENBAUM CM, Filmar S, Gross AJ, Jobst N, et al
The influence of socioeconomic status and gender on incidence and survival in
bladder cancer: a longitudinal study based on the Hamburg Cancer Registry.
World J Urol. 2024;42:166.
- SUARTZ CV, Cordeiro MD, Botelho LAA, Gallucci FP, et al
Predicting individual outcomes after radical cystectomy in urothelial variants
with Cancer of the Bladder Risk Assessment (COBRA) score.
World J Urol. 2024;42:155.
- PYRGIDIS N, Schulz GB, Volz Y, Ebner B, et al
The impact of perioperative risk factors on long-term survival after radical
cystectomy: a prospective, high-volume cohort study.
World J Urol. 2024;42:164.
Zhonghua Zhong Liu Za Zhi
- WEI T, Yuan P
[Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor
with low HER-2 expression].
Zhonghua Zhong Liu Za Zhi. 2024;46:211-220.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016